Stay updated on Tucatinib vs. Placebo with T-DM1 in HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Tucatinib vs. Placebo with T-DM1 in HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib vs. Placebo with T-DM1 in HER2+ Breast Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 6 to 7, indicating a recent update in the context of Medical and healthcare-related publications and documentation.
    Difference
    0.3%
    Check dated 2024-05-22T07:30:20.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    19 days ago
    Change Detected
    Summary
    The value 04 16 has been updated to 05 07 on the webpage, indicating a recent change in the study details related to a clinical trial comparing Tucatinib vs. Placebo in combination with Ado-trastuzumab Emtansine for patients with advanced or metastatic HER2+ breast cancer.
    Difference
    0.7%
    Check dated 2024-05-07T19:55:03.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T22:14:30.000Z thumbnail image

Stay in the know with updates to Tucatinib vs. Placebo with T-DM1 in HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib vs. Placebo with T-DM1 in HER2+ Breast Cancer Clinical Trial page.